Immix: 2nd Orphan Status for Candidate

 FDA Orphan Drug Designation (“ODD”) qualifies one-time treatment NXC-201 for:

• 7 years of U.S. market exclusivity after approval

• Tax credits for qualified clinical testing

• Waiver of the Prescription Drug User Fee (currently at almost $3 million for a new drug)

• The Amyloidosis market was $3.6 billion in 2017, expected to reach $6 billion in 2025, according to Grand View Research

https://finance.yahoo.com/news/u-food-drug-administration-approves-125500986.html